HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## : Colorectal Adjuvant FOLFOX (a7) - JSON Representation

Active as of 2020-06-29

Raw json | Download

    {
      "resourceType" : "PlanDefinition",
      "id" : "ColoRectal",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"
        ]
      },
      "text" : {
        "status" : "additional",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Plan for ColoRectal cancer. There is a single cycle with 2 drug administrations</div>"
      },
      "contained" : [
        {
          "resourceType" : "ActivityDefinition",
          "id" : "ActTragacanth",
          "meta" : {
            "profile" : [
              🔗 "http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"
            ]
          },
          "text" : {
            "status" : "additional",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Tragacanth administration, 3mg over 3 hours by continuous IV infusion</div>"
          },
          "status" : "draft",
          "productCodeableConcept" : {
            "coding" : [
              {
                "system" : "https://nzulm.org.nz/nzmt",
                "code" : "10711851000116105",
                "display" : "Tragacanth"
              }
            ]
          },
          "dosage" : [
            {
              "text" : "3 mg over 3 hours by IV infusion",
              "route" : {
                "coding" : [
                  {
                    "system" : "http://snomed.info/sct",
                    "code" : "180177004",
                    "display" : "continuous intravenous infusion"
                  }
                ]
              },
              "doseAndRate" : [
                {
                  "doseQuantity" : {
                    "value" : 3,
                    "system" : "http://unitsofmeasure.org",
                    "code" : "mg"
                  },
                  "rateQuantity" : {
                    "value" : 3,
                    "system" : "http://unitsofmeasure.org",
                    "code" : "h"
                  }
                }
              ]
            }
          ]
        }
      ],
      "extension" : [
        {
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
          "valueMarkdown" : "Only for women"
        },
        {
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer",
          "valueMarkdown" : "Developed with the best of intentions."
        },
        {
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-regimen-type",
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "dummy"
              }
            ],
            "text" : "Folfox"
          }
        },
        {
          "extension" : [
            {
              "url" : "factor",
              "valueCodeableConcept" : {
                "coding" : [
                  {
                    "system" : "http://snomed.info/sct",
                    "code" : "TOUPDATE-SUPPORT4",
                    "display" : "Diarrhoea risk"
                  }
                ]
              }
            },
            {
              "url" : "value",
              "valueCodeableConcept" : {
                "text" : "low"
              }
            }
          ],
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
        },
        {
          "extension" : [
            {
              "url" : "factor",
              "valueCodeableConcept" : {
                "coding" : [
                  {
                    "system" : "http://snomed.info/sct",
                    "code" : "TOUPDATE-SUPPORT8",
                    "display" : "AntiFungal Prophylaxis"
                  }
                ]
              }
            },
            {
              "url" : "value",
              "valueCodeableConcept" : {
                "text" : "low"
              }
            }
          ],
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
        },
        {
          "extension" : [
            {
              "url" : "factor",
              "valueCodeableConcept" : {
                "coding" : [
                  {
                    "system" : "http://snomed.info/sct",
                    "code" : "TOUPDATE-SUPPORT2",
                    "display" : "Hypersensitivity / Infusion related reaction ris"
                  }
                ]
              }
            },
            {
              "url" : "value",
              "valueCodeableConcept" : {
                "text" : "low"
              }
            }
          ],
          "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
        }
      ],
      "url" : "http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal",
      "version" : "0.1.0",
      "title" : "Colorectal Adjuvant FOLFOX (a7)",
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
            "code" : "clinical-protocol"
          }
        ]
      },
      "status" : "active",
      "_status" : {
        "extension" : [
          {
            "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-additional-plan-status",
            "valueCode" : "review"
          }
        ]
      },
      "experimental" : false,
      "date" : "2020-06-29T20:14:18.417+12:00",
      "publisher" : "Te Aho o Te Kahu, Cancer Control Agency",
      "description" : "A drug treatment regimen for Colorectal cancer. Plan is still under review.",
      "useContext" : [
        {
          "code" : {
            "system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
            "code" : "focus"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "781382000",
                "display" : "Colorectal cancer"
              }
            ]
          }
        }
      ],
      "relatedArtifact" : [
        {
          "type" : "citation",
          "display" : "test",
          "url" : "http://www.ncbi.nlm.nih.gov/pubmed/23434",
          "document" : {
            "url" : "http://www.ncbi.nlm.nih.gov/pubmed/23434"
          }
        },
        {
          "type" : "citation",
          "display" : "test2",
          "url" : "http://www.ncbi.nlm.nih.gov/pubmed/34324",
          "document" : {
            "url" : "http://www.ncbi.nlm.nih.gov/pubmed/34324"
          }
        }
      ],
      "action" : [
        {
          "extension" : [
            {
              "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
              "valueMarkdown" : "Ensure not pregnant before starting"
            }
          ],
          "title" : "This is the only cycle in the regimen.",
          "description" : "Administration of Cabergoline and Tragacanth. Cycle length 14 days",
          "timingTiming" : {
            "repeat" : {
              "count" : 1,
              "duration" : 14,
              "durationUnit" : "d"
            }
          },
          "selectionBehavior" : "all",
          "action" : [
            {
              "extension" : [
                {
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
                  "valueMarkdown" : "Keep a close eye for side effects"
                },
                {
                  "extension" : [
                    {
                      "url" : "day",
                      "valueInteger" : 1
                    },
                    {
                      "url" : "instructions",
                      "valueString" : "Specific instructions for the day 1 administration"
                    }
                  ],
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
                },
                {
                  "extension" : [
                    {
                      "url" : "day",
                      "valueInteger" : 4
                    },
                    {
                      "url" : "instructions",
                      "valueString" : "Specific instructions for the day 4 administration"
                    }
                  ],
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
                }
              ],
              "description" : "2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes",
              "definitionCanonical" : "#act-cabergoline"
            },
            {
              "extension" : [
                {
                  "extension" : [
                    {
                      "url" : "day",
                      "valueInteger" : 2
                    },
                    {
                      "url" : "instructions",
                      "valueString" : "Specific instructions for the day 2 administration"
                    }
                  ],
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
                },
                {
                  "extension" : [
                    {
                      "url" : "day",
                      "valueInteger" : 3
                    },
                    {
                      "url" : "instructions",
                      "valueString" : "Specific instructions for the day 3 administration"
                    }
                  ],
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
                },
                {
                  "extension" : [
                    {
                      "url" : "day",
                      "valueInteger" : 4
                    },
                    {
                      "url" : "instructions",
                      "valueString" : "Specific instructions for the day 4 administration"
                    }
                  ],
                  "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
                }
              ],
              "description" : "3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours",
              "definitionCanonical" : "#act-tragacanth"
            }
          ]
        }
      ]
    }